The company is seeking approval from the US regulator for Vraylar (cariprazine) as an add-on to conventional antidepressant therapy in people with MDD who may be struggling to control symptoms ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in ...

Dec. 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR ® (cariprazine) as an adjunctive therapy to antidepressants ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Vraylar (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in ...

The FDA has approved the use of Vraylar (cariprazine; Allergan) to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. The Food and Drug Administration ...

A patient with depression says she was "stuck" until AbbVie's Vraylar gave her "a lift," which ... alongside an antidepressant therapy. That label boost should help the drug hit $4 billion in ...

and the pharma says it will lean on its marketing work for its atypical antipsychotic drug Vraylar to position this therapy while also looking to carve out a new message. “We have put a lot of ...

Allergan and Richter push ahead despite PhIII fail for depression drug Vraylar brought in $1.73 billion for AbbVie in 2021 and is indicated for bipolar I disorder and schizophrenia. The therapy ...

VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...